Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01938378 · ClinicalTrials.gov registry record · Phase 4
Octaplas Pediatric Plasma Exchange Trial
A Phase 4 study of Adverse Effects in the Therapeutic Use of Plasma Substitutes, sponsored by Octapharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
- 8
- Study locations
NCT01938378 is a Phase 4 study of Adverse Effects in the Therapeutic Use of Plasma Substitutes that has completed, run by Octapharma. The registered enrollment target is 41 participants. The trial reports 8 study locations across 7 states.
The verdict
NCT01938378, a Phase 4 study of Adverse Effects in the Therapeutic Use of Plasma Substitutes, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
- 8
- Study locations
Study Summary
To assess the safety and tolerability of octaplas™ in the pediatric population by monitoring serious adverse drug reactions, adverse drug reactions (ADRs), thrombotic events (TEs), thromboembolic events (TEEs) and by measuring safety laboratory parameters in pediatric patients who require therapeutic plasma exchange.
Conditions Studied
Interventions
- BIOLOGICAL Octaplas™
Study Locations (8)
Missouri
- Octapharma Research Site - Kansas City
- Octapharma Research Site - St Louis
Alabama
- Octapharma Research Site - Birmingham
Georgia
- Octapharma Research Site - Atlanta
Louisiana
- Octapharma Research Site - New Orleans
Minnesota
- Octapharma Research Site - Minneapolis
North Carolina
- Octapharma Research Site - Durham
Ohio
- Octapharma Research Site - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-01-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01938378
The ClinicalTrials.gov registry entry for NCT01938378 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adverse Effects in the Therapeutic Use of Plasma Substitutes appearing as the primary indexed condition, and to 1 intervention - of which Octaplas™ is the first listed.
NCT01938378 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Missouri, Alabama, Georgia.
Frequently Asked Questions
What is clinical trial NCT01938378 about?
NCT01938378 is a clinical study titled "Octaplas Pediatric Plasma Exchange Trial". To assess the safety and tolerability of octaplas™ in the pediatric population by monitoring serious adverse drug reactions, adverse drug reactions (ADRs), thrombotic events (TEs), thromboembolic events (TEEs) and by measuring safety laboratory parameters in pediatric patients who require therapeuti...
What is the current status of trial NCT01938378?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2015-04. Estimated completion is 2019-01-27.
What conditions does trial NCT01938378 study?
This clinical trial studies the following conditions: Adverse Effects in the Therapeutic Use of Plasma Substitutes.
What interventions are being tested in trial NCT01938378?
The interventions under investigation include: Octaplas™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT01938378?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01938378 being conducted?
This trial has 8 study locations across Alabama, Georgia, Louisiana, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.